Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping — Stella

Home/Moderate to Severe Asthma/Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

View on ClinicalTrials.gov

Recruiting

Back to Moderate to Severe Asthma trials

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(3 sites)

United States

Mayo Clinic, Scottsdale, Arizona

University of California, San Diego, La Jolla, California

Yale University, New Haven, Connecticut

Key details

Phase

Post-approval study

Sponsor

University of California, San Diego

Collaborators

Mayo Clinic, Yale University

Enrollment target

~120 participants

Started

February 2024

Primary completion

June 2027

Age range

18 Years – 75 Years

Last updated August 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.